Case report reveals euglycaemic ketoacidosis in a type 2 diabetes patient on SGLT-2 inhibitors, suggesting awareness is needed.
Euglycaemic ketoacidosis (EDKA) is a rare, life-threatening complication of sodium-glucose co-transporter 2 (SGLT-2) inhibitors. With their increasing use in the management of type 2 diabetes(T2DM) and heart failure due to long-term beneficial effects, the incidence of this complication is on the rise. We report a case of a 44-year-old female with T2DM on multiple oral hypoglycaemic agents, including empagliflozin, who developed EDKA during intercurrent illness.
No takes yet. Share an insight, caveat, or question.
Karthika et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: